You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR OXYTOCIN 10 USP UNITS IN DEXTROSE 5%


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00107874 ↗ Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section Completed Basel Women’s University Hospital Phase 2 1999-01-01 Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00107874 ↗ Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section Completed University Hospital, Basel, Switzerland Phase 2 1999-01-01 Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00114439 ↗ Lithium Cannabis Withdrawal Study Completed The University of New South Wales Phase 2 2005-09-01 This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.
NCT00114439 ↗ Lithium Cannabis Withdrawal Study Completed Sydney South West Area Health Service Phase 2 2005-09-01 This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.
NCT00116350 ↗ Misoprostol for the Treatment of Postpartum Hemorrhage Completed Family Care International N/A 2005-07-01 The purpose of this study is to test whether misoprostol is as effective as oxytocin for treating primary postpartum hemorrhage (PPH) with uterine atony as the suspected cause in two circumstances: 1) where women have received prophylactic uterotonics in the third stage of labor; and 2) where no prophylactic uterotonics have been given in the third stage of labor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

Condition Name

Condition Name for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Intervention Trials
Postpartum Hemorrhage 85
Healthy 55
Schizophrenia 30
Oxytocin 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Intervention Trials
Hemorrhage 161
Postpartum Hemorrhage 142
Disease 37
Schizophrenia 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

Trials by Country

Trials by Country for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Location Trials
United States 366
Egypt 87
Canada 64
China 49
France 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Location Trials
California 61
North Carolina 33
New York 31
Massachusetts 29
South Carolina 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

Clinical Trial Phase

Clinical Trial Phase for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Clinical Trial Phase Trials
Phase 4 129
Phase 3 66
Phase 2/Phase 3 17
[disabled in preview] 502
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Clinical Trial Phase Trials
Completed 391
Recruiting 118
Unknown status 97
[disabled in preview] 147
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

Sponsor Name

Sponsor Name for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Sponsor Trials
University of Electronic Science and Technology of China 40
Samuel Lunenfeld Research Institute, Mount Sinai Hospital 29
Cairo University 24
[disabled in preview] 61
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Sponsor Trials
Other 1000
Industry 52
NIH 39
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.